Delayed sustained release pharmaceutical compositions that provide therapeutic effects over extended periods of time (i.e., 14-16 hours).

The present invention relates to a novel pharmaceutical composition of Tamsulosin and Dutasteride and process of manufacture thereof. Specifically, the present invention relates to multiparticulate(s) of Tamsulosin and Dutasteride filled in capsule or/compressed in tablet dosage form and process of manufacture thereof.

Described herein is a composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients. The microparticles (crystals, granules, beads or pellets containing the active) are coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

An aqueous liquid suspension containing a coated drug—ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine—ion exchange resin complex is provided. The coated amphetamine—ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.

The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I) or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.

##STR00001##

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.